Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$4.74 - $6.81 $569,928 - $818,820
-120,238 Reduced 81.49%
27,312 $162,000
Q4 2023

Feb 14, 2024

SELL
$2.93 - $7.32 $46,880 - $117,120
-16,000 Reduced 9.78%
147,550 $1.08 Million
Q3 2023

Nov 14, 2023

BUY
$3.75 - $7.46 $82,500 - $164,120
22,000 Added 15.54%
163,550 $635,000
Q2 2023

Aug 14, 2023

BUY
$5.32 - $6.79 $139,384 - $177,898
26,200 Added 22.71%
141,550 $817,000
Q1 2023

May 12, 2023

BUY
$2.88 - $8.51 $46,080 - $136,160
16,000 Added 16.1%
115,350 $750,000
Q4 2022

Feb 13, 2023

BUY
$2.09 - $3.39 $19,646 - $31,866
9,400 Added 10.45%
99,350 $273,000
Q3 2022

Nov 14, 2022

BUY
$2.17 - $4.3 $99,928 - $198,015
46,050 Added 104.9%
89,950 $263,000
Q2 2022

Aug 12, 2022

SELL
$1.81 - $8.93 $30,046 - $148,238
-16,600 Reduced 27.44%
43,900 $84,000
Q1 2022

May 13, 2022

BUY
$7.59 - $9.49 $73,053 - $91,341
9,625 Added 18.92%
60,500 $491,000
Q4 2021

Feb 14, 2022

BUY
$9.1 - $13.36 $54,600 - $80,160
6,000 Added 13.37%
50,875 $466,000
Q3 2021

Nov 15, 2021

BUY
$9.55 - $13.96 $99,320 - $145,184
10,400 Added 30.17%
44,875 $561,000
Q2 2021

Aug 13, 2021

BUY
$9.77 - $15.33 $130,918 - $205,422
13,400 Added 63.58%
34,475 $390,000
Q1 2021

May 14, 2021

SELL
$10.51 - $17.46 $57,805 - $96,030
-5,500 Reduced 20.7%
21,075 $319,000
Q4 2020

Feb 12, 2021

BUY
$7.41 - $12.63 $111,705 - $190,397
15,075 Added 131.09%
26,575 $306,000
Q3 2020

Nov 13, 2020

BUY
$6.16 - $10.3 $70,840 - $118,450
11,500 New
11,500 $89,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Mml Investors Services, LLC Portfolio

Follow Mml Investors Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mml Investors Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mml Investors Services, LLC with notifications on news.